8JM Stock Overview
Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas, and the Asia Pacific region.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 5/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
Rewards
Risk Analysis
No risks detected for 8JM from our risk checks.
Vetoquinol SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €94.20 |
| 52 Week High | €108.20 |
| 52 Week Low | €76.40 |
| Beta | 0.91 |
| 1 Month Change | 0% |
| 3 Month Change | -9.07% |
| 1 Year Change | 0.96% |
| 3 Year Change | -9.77% |
| 5 Year Change | n/a |
| Change since IPO | -11.96% |
Recent News & Updates
Recent updates
Shareholder Returns
| 8JM | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -4.9% | 1.5% | -1.0% |
| 1Y | 1.0% | -26.5% | 2.2% |
Return vs Industry: 8JM exceeded the German Pharmaceuticals industry which returned -26.5% over the past year.
Return vs Market: 8JM underperformed the German Market which returned 2.2% over the past year.
Price Volatility
| 8JM volatility | |
|---|---|
| 8JM Average Weekly Movement | 3.7% |
| Pharmaceuticals Industry Average Movement | 7.1% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 8JM has not had significant price volatility in the past 3 months.
Volatility Over Time: 8JM's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1933 | 2,497 | Matthieu Frechin | www.vetoquinol.com |
Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas, and the Asia Pacific region. It provides products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; infectious diseases; reproduction; behavior management; internal medicine; and cardiology-nephrology for cattle, sheep, pigs, poultry, dogs, cats, and horses. The company was founded in 1933 and is headquartered in Lure, France.
Vetoquinol SA Fundamentals Summary
| 8JM fundamental statistics | |
|---|---|
| Market cap | €1.11b |
| Earnings (TTM) | €55.60m |
| Revenue (TTM) | €529.30m |
20.0x
P/E Ratio2.1x
P/S RatioIs 8JM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 8JM income statement (TTM) | |
|---|---|
| Revenue | €529.30m |
| Cost of Revenue | €0 |
| Gross Profit | €529.30m |
| Other Expenses | €473.70m |
| Earnings | €55.60m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Sep 12, 2024
| Earnings per share (EPS) | 4.70 |
| Gross Margin | 100.00% |
| Net Profit Margin | 10.50% |
| Debt/Equity Ratio | 3.1% |
How did 8JM perform over the long term?
See historical performance and comparisonDividends
0.9%
Current Dividend Yield16%
Payout RatioDoes 8JM pay a reliable dividends?
See 8JM dividend history and benchmarks| Vetoquinol dividend dates | |
|---|---|
| Ex Dividend Date | Jun 04 2024 |
| Dividend Pay Date | Jun 06 2024 |
| Days until Ex dividend | 28 days |
| Days until Dividend pay date | 30 days |
Does 8JM pay a reliable dividends?
See 8JM dividend history and benchmarks